

#### Correction

# Correction: Cook et al. An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats. *Viruses* 2022, 14, 2429

Sarah Cook <sup>1,\*</sup>, Luke Wittenburg <sup>2</sup>, Victoria C. Yan <sup>3</sup>, Jacob H. Theil <sup>4</sup>, Diego Castillo <sup>1</sup>, Krystle L. Reagan <sup>5</sup>, Sonyia Williams <sup>1</sup>, Cong-Dat Pham <sup>3</sup>, Chun Li <sup>3</sup>, Florian L. Muller <sup>6</sup> and Brian G. Murphy <sup>1</sup>

- <sup>1</sup> Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616, USA; ldcastillo@ucdavis.edu (D.C.); sywilliams@ucdavis.edu (S.W.); bmurphy@ucdavis.edu (B.G.M.)
- <sup>2</sup> Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616, USA; lwittenburg@ucdavis.edu
- <sup>3</sup> Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; yan22v@mtholyoke.edu (V.C.Y.); cpham3@mdanderson.org (C.-D.P.); cli@mdanderson.org (C.L.)
- <sup>4</sup> Office of Research, Campus Veterinary Services, University of California-Davis, Davis, CA 95616, USA; jhtheil@ucdavis.edu
- <sup>5</sup> Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616, USA; kreagan@ucdavis.edu
- <sup>6</sup> Sporos Bioventures, @JLABS Suite 201, 2450 Holcombe Blvd, Houston, TX 77021, USA; aettius@aol.com
- Correspondence: sestevens@ucdavis.edu

## Error in Table

In the original publication [1], incorrect numerical data were entered into the last three numbers in the AUC column of Table 5 and this mistake was not recognized by our review team. This error was identified by Sally Coggins who brought it to our attention. Corrected Table 5 appears below.

Table 5. Pharmacokinetic parameters for GS-441524 after a single IV dose of RDV (7 mg/kg) in 3 cats.

Cat ID	C <sub>max</sub> (ng/mL; μM)	T <sub>max</sub> (h)	T <sub>1/2</sub> (h)	AUC (h*ng/mL)
20-045	1730 (5.94)	0.5	5.3	14,271
21-001	1960 (6.73)	1	5.7	15,291
21-004	2320 (7.97)	1	4.5	9924
Mean	2003 (6.88)	0.83	5.2	13,162
SD	297 (1.0)	0.29	0.6	2850

## **Text Correction**

With regard to the correction of Table 5, a correction has been made to Section 3.4, Paragraph 3.

"Finally, in the IV RDV cohort, GS-441524 exhibited an average plasma Cmax of 2003 ng/mL (6.9  $\mu$ M) at a corresponding Tmax of 0.83 h and an average AUC<sub>0-24</sub> value of 13,162 h\*ng/mL (45  $\mu$ M\*h; average C24 = 64  $\pm$  32 ng/mL, 0.22  $\pm$  0.11  $\mu$ M) (Table 5)."



Citation: Cook, S.; Wittenburg, L.; Yan, V.C.; Theil, J.H.; Castillo, D.; Reagan, K.L.; Williams, S.; Pham, C.-D.; Li, C.; Muller, F.L.; et al. Correction: Cook et al. An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats. *Viruses* 2022, 14, 2429. *Viruses* 2024, 16, 397. https:// doi.org/10.3390/v16030397

Received: 19 February 2024 Accepted: 19 February 2024 Published: 4 March 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).



2 of 2

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

#### Reference

1. Cook, S.; Wittenburg, L.; Yan, V.C.; Theil, J.H.; Castillo, D.; Reagan, K.; Williams, S.; Pham, C.-D.; Li, C.; Muller, F.L.; et al. An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats. *Viruses* **2022**, *14*, 2429. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.